What is the primary concern regarding the use of SSRIs during pregnancy, particularly for neonates?

The primary concern associated with the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy, particularly for neonates, relates to the increased rates of pulmonary hypertension. This condition, known as persistent pulmonary hypertension of the newborn (PPHN), has been observed in some studies indicating a potential correlation with SSRI exposure in utero. PPHN is a serious condition where a newborn’s circulation system doesn’t transition properly after birth, leading to inadequate oxygenation and potentially significant complications.

While other concerns regarding the use of SSRIs in pregnancy exist, such as the risk of neural tube defects or other pregnancy complications, the more acute focus on neonatal outcomes highlights the association with PPHN as an emerging clinical consideration. It's essential for healthcare providers to weigh these risks when prescribing SSRIs to pregnant individuals, ensuring they are providing comprehensive care that considers both maternal mental health and neonatal safety.